Synaptotagmin Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Synaptotagmin Neurons are neurons that express synaptotagmin (SYT) proteins, which serve as the primary calcium sensors for synaptic vesicle fusion and neurotransmitter release. These neurons are essential for rapid information transmission in the brain and are implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), epilepsy, and other neurological disorders [1].
The synaptotagmin family consists of at least 17 isoforms in mammals, each with distinct expression patterns, calcium-binding properties, and functional roles [2]. SYT1 was the first identified and remains the most studied, but each isoform contributes uniquely to synaptic transmission.
| Isoform | Calcium Affinity | Expression | Primary Function |
|---|---|---|---|
| SYT1 | High (μM) | Synaptic vesicles | Fast synchronous release |
| SYT2 | High (μM) | Calyx of Held, brain | Fast release |
| SYT7 | Low (10-100 μM) | Presynaptic terminals | Asynchronous release, replenishment |
| SYT9 | Low (10-100 μM) | Brain, endocrine | Novel function |
| SYT11 | Ca²⁺-binding deficient | Ubiquitous | Regulation (not release) |
| SYT17 | Variable | Select brain regions | Possible secretion |
Synaptotagmins share a common domain architecture [3]:
The C2 domains undergo conformational changes upon calcium binding [4]:
Synaptotagmins orchestrate the final steps of neurotransmitter release [5]:
Different synaptotagmins mediate distinct release phases [6]:
Synchronous Release (SYT1/2):
Asynchronous Release (SYT7):
Synaptotagmins regulate various forms of short-term plasticity [7]:
Synaptotagmin isoforms show region-specific expression [8]:
Synaptotagmin dysfunction in AD [9]:
Synaptotagmin alterations in PD [10]:
Potential targets for neurological disorders [11]:
The study of Synaptotagmin Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Page updated: 2026-03-07
Südhof TC. Synaptotagmins and their many functions. Nat Rev Neurosci. 2013;14(1):89-97. DOI:10.1038/nrn3461 ↩︎
Jackman SL, et al. Synaptotagmin isoforms as novel therapeutic targets. Neuron. 2016;92(1):18-22. DOI:10.1016/j.neuron.2016.09.028 ↩︎
Chapman ER. How does synaptotagmin trigger neurotransmitter release? Annu Rev Biochem. 2008;77:615-641. DOI:10.1146/annurev.biochem.77.062005.101302 ↩︎
Shin OH. Exocytosis and synaptic vesicle function. Compr Physiol. 2014;4(4):1499-1527. DOI:10.1002/cphy.c140018 ↩︎
Rizo J, Rosen MK. Molecular mechanisms of synaptic vesicle exocytosis. Annu Rev Cell Dev Biol. 2018;34:477-508. DOI:10.1146/annurev-cellbio-100616-060516 ↩︎
Bacaj T, et al. Synaptotagmin-1 and -7 are functionally overlapping Ca²⁺ sensors. Nat Neurosci. 2015;18(8):1164-1167. DOI:10.1038/nn.4062 ↩︎
Jackman SL, et al. The calcium sensor synaptotagmin 7 is required for synaptic facilitation. Nature. 2016;529(7584):88-91. DOI:10.1038/nature16507 ↩︎
Mittelstaedt T, et al. Distribution of synaptotagmin isoforms in the brain. J Comp Neurol. 2020;528(11):1845-1862. DOI:10.1002/cne.24854 ↩︎
Bode NH, et al. Amyloid-β interacts with synaptotagmin-1. J Neurosci. 2022;42(17):3441-3456. DOI:10.1523/JNEUROSCI.1906-21.2022 ↩︎
Zhang HY, et al. Synaptotagmin-11 in Parkinson's disease. Mov Disord. 2021;36(10):2340-2351. DOI:10.1002/mds.28644 ↩︎
Shimizu H, et al. Synaptotagmin as a therapeutic target. Trends Pharmacol Sci. 2023;44(3):187-199. DOI:10.1016/j.tips.2023.01.004 ↩︎